Methods of transplanting chondrocytes

Abstract

Provided are tri-component matrices having collagen, hyaluronan, and chondroitin sulfate. Also provided are processes for producing a tri-component matrix. Additionally, provided are processes for providing cells capable of producing cartilage to a bone or cartilage defects.

1 .- 15 . (canceled) 
     
     
         16 . A process for producing a transplantation composition for cartilage engineering comprising:
 a) dissolving 0.5 mg to 5 mg of type II collagen per milliliter of a solution comprising an acid;   b) neutralizing the acid;   c) adding 0.25 mg to 3 mg of hyaluronan per milliliter of the solution; and   d) adding 0.25 mg to 3 mg of chondroitin sulfate per milliliter of the solution,   thereby producing a transplantation composition comprising a tri component matrix.   
     
     
         17 . The process of  claim 16 , wherein the acid is acetic acid. 
     
     
         18 . The process of  claim 16 , wherein the acetic acid is at a concentration of 0.01 M. 
     
     
         19 . The process of  claim 16 , wherein the acetic acid is neutralized with NaHCO 3  and HEPES. 
     
     
         20 . The process of  claim 16 , further comprising adding Medium 199 to the tri-component matrix. 
     
     
         21 . The process of  claim 16 , wherein step (c) comprises adding 1 mg/ml 1 mg of hyaluronan per milliliter of the solution. 
     
     
         22 . The process of  claim 16 , wherein step (d) comprises adding 1 mg/ml 1 mg of chondroitin sulfate per milliliter of the solution. 
     
     
         23 . The process of  claim 16 , wherein step (a) comprises dissolving 3 mg/ml 3 mg of type II collagen per milliliter of the solution. 
     
     
         24 . The process of  claim 16 , further comprising adding a plurality of cells comprising chondrocytes, chondroprogenitor cells, mesenchymal stem cells, iPS cells, iPS cells derived from chondrocytes, H9-derived chondroprogenitor cells, Sox-9 transduced chondrocytes, or any combinations thereof, to the tri-component matrix. 
     
     
         25 . The process of  claim 24 , wherein adding the plurality of cells comprises adding chondrocytes to the tri-component matrix. 
     
     
         26 . The process of  claim 24 , wherein adding the plurality of cells comprises adding chondroprogenitor cells to the tri-component matrix. 
     
     
         27 . The process of  claim 24 , wherein adding the plurality of cells comprises adding iPS cells to the tri-component matrix. 
     
     
         28 - 49 . (canceled) 
     
     
         50 . The process of  claim 16 , further comprising adding a fibrin adhesive to the tri-component matrix. 
     
     
         51 . The process of  claim 16  wherein the type II collagen is isolated type II collagen. 
     
     
         52 . The process of  claim 16  wherein the type II collagen is purified type II collagen. 
     
     
         53 . The process of  claim 16  wherein the type II collagen is non-denatured type II collagen. 
     
     
         54 . The process of  claim 53  wherein the non-denatured type II collagen is purified non-denatured type II collagen.